Clinical Trials Logo

Vagus Nerve Stimulation clinical trials

View clinical trials related to Vagus Nerve Stimulation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06421090 Recruiting - Clinical trials for Vagus Nerve Stimulation

Transauricular Vagal Nerve Stimulation Improves Postoperative Delirium in Elderly Patients

Vnstar-IIa
Start date: May 21, 2024
Phase: N/A
Study type: Interventional

To investigate the efficacy and safety of perioperative Transauricular vagal nerve stimulation in improving Postoperative Delirium in elderly patients undergoing elective surgery Lay the groundwork for a Phase III study.

NCT ID: NCT06421077 Recruiting - Clinical trials for Vagus Nerve Stimulation

Transauricular Vagus Nerve Stimulation Improves Postoperative Delirium in Elderly Patients

Vnstar
Start date: May 21, 2024
Phase: N/A
Study type: Interventional

According to the 3D-CAM scale, evaluate the incidence of Postoperative Delirium within 5 days after surgery in elderly patients receiving Transauricular vagal nerve stimulation.The results are expected to provide evidence of the safety and efficacy of perioperative prophylactic use of taVNS in the clinical application of improving postoperative brain health in elderly patients, as well as theoretical and practical basis for subsequent studies or clinical applications.

NCT ID: NCT05992259 Recruiting - Clinical trials for Acute Coronary Syndrome

Auricular Vagus Stimulation and STEMI

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

At the moment, the invasive strategy for the infarct-associated coronary artery in patients with ST-segment elevation myocardial infarction (STEMI) necessary to save the myocardium and reduce the size of the necrosis zone remains the leading one. However, despite the high efficiency of providing medical care to patients with acute coronary syndrome (ACS), there remains a high mortality and disability of this group of patients. In this regard, the search for new drug and non-drug strategies for the treatment of patients with ACS is actively continuing. Over the past decade, it has been shown that transcutaneous vagus nerve stimulation (TENS) has a cardioprotective effect both in chronic heart failure and in coronary heart disease, improves cardiac function, prevents reperfusion injury, weakens myocardial remodeling, increases the effectiveness of defibrillation and reduces the size of a heart attack. One of the methods of noninvasive stimulation of the afferent fibers of the vagus nerve is percutaneous electrical stimulation of the auricular branch of the vagus nerve. However, further studies are needed to determine whether stimulation of the tragus can improve the long-term clinical outcome in this cohort of patients.

NCT ID: NCT05680337 Recruiting - Clinical trials for Heart Rate Variability

Auricular Vagus Stimulation and Heart Rate Variability

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

Transcutaneous electrical stimulation of the auricular vagus nerve (TENS) is a promising method of neuromodulation of the autonomic nervous system in patients with various pathologies. The use of this method requires the determination of a reliable biomarker of successful activation of the vagus nerve using TENS. Currently, most studies focus on the assessment of heart rate variability (HRV) as a marker of the functioning of the autonomic nervous system. Despite the physiological justification of HRV as a biomarker for TENS, the data on the effects of TENS on HRV are ambiguous. In some studies, a significant decrease in the ratio of spectral characteristics (LF/HF) in active TENS was found in comparison with fictitious stimulation (sham), which indicated an increase in the parasympathetic component of HRV. However, other studies have not revealed an increase in HRV.

NCT ID: NCT05343039 Recruiting - Alcohol Abuse Clinical Trials

Technology Enhanced Adolescent Mental Health (TEAM)

TEAM
Start date: September 6, 2022
Phase: N/A
Study type: Interventional

Adolescent nonsuicidal self-injury (NSSI) and alcohol misuse, alone and especially in combination, portend significant functional impairment in adulthood (e.g., relationship dysfunction, depression, suicidality). Although psychosocial interventions for NSSI and substance use are effective for some, they are also expensive and require highly trained clinicians. Treatment is therefore often unavailable to disadvantaged adolescents and those who live rurally. Thus, lower-cost alternative treatments are needed. We will evaluate the efficacy of noninvasive transcutaneous vagus nerve stimulation (tVNS), an effective treatment for depression, in reducing risk for NSSI and substance misuse among vulnerable adolescents.